AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 147 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $20,000 | – | 752 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital LLC | 1,240,000 | $25,966,000 | 57.34% |
| Foresite Capital Management II, LLC | 2,605,499 | $54,559,000 | 11.53% |
| Foresite Capital Management III, LLC | 611,893 | $12,813,000 | 4.89% |
| Palo Alto Investors LP | 3,471,740 | $72,698,000 | 4.84% |
| SANDERS MORRIS HARRIS LLC | 486,906 | $10,196,000 | 2.47% |
| Eventide Asset Management | 3,084,000 | $64,579,000 | 2.13% |
| Sofinnova Investments, Inc. | 346,770 | $7,261,000 | 0.66% |
| EMERALD ADVISERS, LLC | 610,511 | $12,784,000 | 0.60% |
| RICE HALL JAMES & ASSOCIATES, LLC | 752,358 | $15,754,000 | 0.56% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 587,464 | $12,301,000 | 0.54% |